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Purpose: The purpose of this study was to identify the underlying molecular genetic defect in a large consanguineous
Pakistani family with Oguchi disease who had been given a diagnosis of autosomal recessive retinitis pigmentosa.
Methods: The family was genotyped with the Affymetrix 10K single nucleotide polymorphism array. Fine-mapping of
a common homozygous region on chromosome 13q was performed using fluorescent microsatellite markers. Mutation
analysis was done by direct sequencing of the candidate gene GRK1 located in the region. The segregation of a novel
mutation in the family and the frequency of the identified mutation in the Pakistani population were determined by StuI
RFLP analysis.
Results: Genetic mapping supported the diagnosis of typical Oguchi disease in a Pakistani family and also resulted in the
identification of a novel nonsense mutation (c.614C>A; p.S205X) in exon 1 of GRK1. This mutation is predicted to result
in premature termination of the protein product, thereby affecting the phototransduction cascade. A clinical reappraisal
of the family revealed that all patients homozygous for this variant had Oguchi disease.
Conclusions: This is the first report to describe a mutation causing typical Oguchi disease in a large consanguineous
Pakistani family. This mutation segregated in eight affected members.
Oguchi disease is a rare autosomal recessive form of
congenital stationary night blindness associated with fundus
discoloration and abnormally slow dark adaptation after light
exposure, along with characteristic electroretinographic
(ERG) abnormalities. The disease was first reported by
Oguchi in 1907 as a variant form of congenital stationary night
blindness (CSNB) and was later characterized phenotypically
by Mizuo in 1913 [1], who demonstrated the Mizuo-
Nakamura phenomenon in affected individuals. In this test
after 2–3 h of dark adaptation of the eyes, the diffused yellow
or grey discoloration of the fundus returns to normal, along
with the reappearance of rod function. The discoloration of
the fundus reappears shortly after reexposure to light [2,3].
Oguchi disease has been shown to be more common in the
Japanese population compared to other populations [4]. In
addition to the typical Oguchi disease, variant forms have also
been reported without the typical Mizuo-Nakamura
phenomenon and variable fundus appearances and ERG
patterns [5].
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The first Oguchi locus was located on chromosome
2q37.1 by Maw et al. [6]. Subsequently, mutations in the
arrestin, or S-antigen, gene (SAG) were found to be associated
with Oguchi disease. Later, a mutation in a G-protein-
dependent receptor kinase 1 (GRK1), also called rhodopsin
kinase, which is located on chromosome 13q34, was shown
to result in the Oguchi phenotype [7]. The proteins encoded
by these two genes are members of the phototransduction
pathway in rod photoreceptor cells [4,7]. Here, rhodopsin
kinase (RK) and SAG work sequentially in deactivating the
photoactivated rhodopsin, thereby stopping the
phototransduction cascade.
Rhodopsin kinase is a rod-specific cytosolic enzyme, and
its kinase activity is specifically directed to photoactivated
rhodopsin by phosphorylating multiple serine residues [8].
Various types of mutations, e.g. both missense and protein
truncating, have been shown to result in a decrease in the
catalytic activity of the protein, leading to delayed
photoreceptor recovery. These mutations are mainly
associated with Oguchi disease [7,9,10], although one report
describes the association of GRK1 mutations with retinitis
pigmentosa (RP) [11].
In this paper, we report a novel nonsense mutation in
GRK1 in affected members of a large consanguineous
Pakistani family. These patients initially were diagnosed with
RP. After identifying the genetic defect in affected family
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members, they were clinically re-evaluated through dark
adaptation testing. The affected individuals were diagnosed
with typical Oguchi disease, a phenotype that has thus far not
been described in the Pakistani population.
METHODS
Clinical evaluations: Twenty-two individuals from family
RP19, including seven females and 15 males ranging in age
from three to 66 years, were ascertained from the central
region of Punjab province of Pakistan. The eight affected
members had previously been diagnosed by a local doctor
with autosomal recessive RP based on their night blindness.
Ninety-three healthy individuals (26 females, 67 males, age
13–60 years) some from central Punjab and most from
different regions of Pakistan, were interviewed to exclude the
presence of RP or any other eye disease. Blood samples were
collected from 22 individuals (eight affected and 14 healthy
individuals) from a five-generation pedigree (Figure 1) who
all consented to participate in the study. In two branches (IV6/
IV7, IV8/IV9, and their children) the parents are first cousins.
A consanguineous relationship between III-1 and III-2 is not
known, although they belong to the same community. The
medical and family history of the participants was then taken
through a questionnaire. Fundoscopy without dark adaptation
test and ERG were performed that didn’t give clear
characteristics of Oguchi disease. Fundoscopy and
electroretinographic (ERG) diagnostic tests were performed
for selected members (IV-3, V-1, and V-2) of the RP19 family.
This study was approved by the Shifa College of Medicine/
Shifa International Hospital Ethics Committee/Institutional
Review Board.
Before the ERG measurements were made, photoreceptor
cells were first dark adapted (scotopic ERG) for 20–30 min to
measure the rod response. Next, the patients were light
adapted for 10 min (photopic ERG) to measure the cone
response. The total (or aggregate) electrical response of the
retina was then recorded with a contact lens electrode using
commercial ERG equipment (LKC Inc., Gaithersburg, MD)
[12].
To confirm the diagnosis of Oguchi disease in this family,
individuals IV-3, V-1, and V-2 were studied by a dark
adaptation test of 2–3 h to observe the changes in the fundus
before and after the onset of light exposure. The fundi were
examined by an indirect ophthalmoscope and 20 diopter lens.
The light intensity of the indirect ophthalmoscope was kept at
the lower levels to gain more time to observe the changes in
the retina.
Molecular genetic studies: Blood samples were drawn using
vacutainer tubes containing acid citrate dextrose (Becton
Dickinson product no 364606, Franklin Lakes, NJ). DNA
isolation was performed by Sambrook’s method (organic
method) of DNA extraction using 4 ml of blood, as described
previously [13]. Six affected members from the fourth and
fifth generation (IV-1, IV-2, IV-3, V-9, V-10, V-11) of the
family (Figure 1) were genotyped with the Affymetrix 10K
Figure 1. RP19 pedigree and 13q32.3-
qter haplotypes. White circles represent
healthy females, filled circles represent
affected females, white squares
represent healthy males, and filled
squares are affected males. Slashed
symbols indicate deceased individuals.
Arrowhead marks the position of the
GRK1 gene at 13q34. The genomic
positions (in Mb) of all the markers are
based on UCSC genome working draft
hg18 (March 2006) and indicated
between brackets.
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single nucleotide polymorphism (SNP) array containing
10,204 SNPs (Affymetrix, Santa Clara, CA). Multipoint
parametric linkage analysis and LOD score calculations were
performed with the GeneHunter program in the EasyLinkage
software package version 5.02 [14] using the Decode Genetics
SNP map and the Asian allele frequencies. An autosomal
recessive mode of inheritance with full penetrance was
assumed, and the disease allele frequency was estimated at
0.001. Fine-mapping of the linkage interval on chromosome
13q was performed with fluorescently labeled microsatellite
markers. These markers were amplified by the polymerase
chain reaction (PCR) under standard PCR conditions, and the
haplotypes were constructed based upon the allele sizes of the
microsatellites. Positions of the microsatellite markers were
derived from the Marshfield map. Two-point parametric
linkage analysis and LOD score calculations of the
microsatellite markers were performed by using the
SuperLink package version 1.6 in the EasyLinkage software
package.
Sequencing primers for GRK1, a candidate gene in the
region, were as previously reported by Zhang et al. [5]. These
were used to amplify all exons of GRK1 in one of the affected
individuals from each branch of the family, along with a
control sample. The amplified PCR products were separated
on agarose gel and purified with the Nucleospin DNA
extraction kit (Nucleospin Extract II, Macherey-Nagel GmbH
& Co, Duren, Germany). Purified products were directly
sequenced using the corresponding primers and dye-
termination chemistry (BigDye Terminator, version 3 on a
3730 or 2100 DNA analyzer; Applied Biosystems, Foster
City, CA).
To determine the presence of the mutation identified in
GRK1, we amplified exon 1 of this gene in all the family
members of family RP19, 42 unrelated Pakistani probands
with RP, and a panel of 93 Pakistani control individuals. The
552 bp fragment was then digested with the restriction enzyme
StuI, and resolved on an agarose (1.5%) gel. PCR products
with the GRK1 mutation were digested into fragments of 186
and 366 bp.
RESULTS
Family RP19 was initially given a diagnosis of autosomal
recessive RP. However, during fundoscopy of the individuals
IV-3 and V-1, no bone spicule deposits were observed in the
fundus (Figure 2A), which are typical for RP. Scotopic ERG
showed a significantly reduced rod response (data not shown).
Six affected family members were analyzed by whole-
genome SNP analysis, which showed homozygosity for a 15.2
Mb region on chromosome 13q34 between SNPs rs1927724
and rs723395 with a maximum LOD score of 3.29. The
segregation of the haplotype among all available family
members was confirmed and expanded by the fluorescently
labeled microsatellite markers between rs1927724 and
rs723395. In this way, the critical region was refined to a 5-
Mb region between D13S1315 (position 109.1 Mb) at the
centromeric side and 13qter (position 114.1 Mb). All eight
affected individuals were homozygous for this chromosomal
interval (Figure 1). At the telomeric side, no recombinations
were observed between the Oguchi phenotype and the most
telomeric analyzed SNP, rs723395. At the centromeric side,
a recombination between D13S1315 and D13S1295 was
deduced between the at risk haplotypes in the unaffected
individuals III-1 or III-2 and IV-5. In addition, affected
individuals V-9 and V-10 show a paternal at risk haplotype
between D13S1315 and 13qter. We observed a maximum
two-point LOD score of 5.1 for marker D13S1295 at theta 0.
Figure 2. Fundus photographs of patient V-1 who has Oguchi disease.
A: Fundus photograph of individual V-1 with Oguchi disease before
dark adaptation. The gray discoloration of the fundus is a
characteristic sign of Oguchi disease. B: Fundus photograph after 2
h of dark adaptation shows normal appearance of the retina.
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One of the genes residing in the homozygous interval was
GRK1 (at 113.3 Mb), in which mutations have been reported
[10] to cause Oguchi disease. All seven coding exons and
flanking intronic sequences of GRK1 were sequenced in
affected family members IV-1, V-5, and V-11. Sequencing
revealed a homozygous change of nucleotide C>A at position
614 in exon 1 of the GRK1 gene in these three patients. This
nucleotide change results in a nonsense mutation, p.S205X
(Figure 3A).
The novel mutation c.614C>A results in the creation of a
restriction site for the StuI restriction enzyme. To determine
the segregation of the mutation, we performed StuI restriction
analysis in all family members, which showed that all parents,
as well as several unaffected siblings, were heterozygous
carriers of the mutation. Eight unaffected individuals were
found to be homozygous for the wild-type sequence (Figure
3B). As expected, all affected individuals were homozygous
for the mutation. No carriers of the c.614C>A variant were
detected after mutation screening of 42 RP probands and 93
Pakistani controls.
Because mutations in GRK1 are mainly associated with
Oguchi disease, clinical characteristics of the affected family
members were reevaluated. Patients of family RP19 turned
out to have an Oguchi phenotype, since the affected
individuals have congenital stationary night blindness and
grey discoloration of the fundus, which are characteristic signs
of the disease. The typical Mizuo-Nakamura phenomenon of
fundus changes for Oguchi was observed in the affected
individuals who were subjected to a dark adaptation of only 2
h. The normal recommended time of dark adaptation is at least
2–3 h to see a clear difference between the light and dark
adapted fundus. The Mizuo-Nakamura phenomenon in the
participants of our study exhibited a less marked
disappearance of the fundus' unusual gray discoloration and
the appearance of the reddish coloration due to reduced time
for dark adaptation (Figure 2B).
DISCUSSION
In this study, we present a Pakistani family (RP19) with
Oguchi disease in whom we found a causative novel protein-
truncating mutation in the GRK1 gene (p.S205X). The
affected members have congenital stationary night blindness
along with diffuse gray discoloration of the fundus and show
the Mizuo-Nakamura phenomenon after dark adaptation of 2
h. ERG data showed nonrecordable rod responses, which is
characteristic for patients affected with Oguchi disease [15].
The Mizuo-Nikamura phenomenon is known to be a specific
sign of Oguchi disease, an unusual form of congenital
stationary night blindness, but has also been described in X-
linked recessive and dominant cone dystrophy, Stargardt
disease, and X-linked retinoschisis [16-19].
In the Japanese and European population, several cases
have been reported in which the causative mutations are either
in the SAG gene, or in the GRK1 gene [20-22]. Oguchi disease
is rare worldwide, while the prevalence is the highest in the
Japanese population [23]. A variant form of Oguchi disease
has also been reported to be caused by a deletion in exon 3 of
the GRK1 gene without the typical Mizuo-Nakamura
phenomenon in the affected individual [5].
The GRK1 gene encodes rhodopsin kinase, a cytosolic
enzyme that belongs to the family of signal-transduction
proteins and mediates cellular responses in the rod
photoreceptor cells. It is a serine-threonine kinase, which
plays a key role in normal deactivation and recovery of the
photoreceptor after exposure to light [9]. In the retina,
desensitization of rod cells occurs when light-activated
Figure 3. Sequence chromatograms and
segregation analysis of the p.S205X
GRK1 variant. A: Sequence
chromatogram of part of exon 1.
Sequence of normal control sample (left
panel) and an affected individual IV-1
(right panel) with the homozygous
mutant sequence c.614C>A. B: StuI
restriction analysis of the 552 bp PCR
products of exon 1 in all family
members. Fragments were resolved on
an 1.5% agarose gel. Individuals with a
single fragment of 552 bp were
identified as homozygous normal since
they did not contain the restriction site
for StuI. Those with three fragments
(552 bp, 366 bp, and 186 bp) were
heterozygous carriers of the mutation,
and those with two fragments (366 bp
and 186 bp) carried the mutation
homozygously.
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rhodopsin is phosphorylated by rhodopsin kinase, followed
by the binding of visual arrestin to the phosphorylated
rhodopsin. In turn, this blocks the interaction of rhodopsin
with transducin, which results in switching off the
phototransduction cascade [24]. As such, rhodopsin kinase is
a crucial factor in regulating the phototransduction cascade
and any defect in its expression is predicted to affect the
normal functioning of the retina.
The work of Choi et al. [25] on Sag/Grk1-deficient mouse
retina has demonstrated the functional importance of
rhodopsin kinase in the phototransduction process. They
showed that when the animals are raised in the dark, they have
normal retinal morphology. However, when exposed to
continuous light, these animals show rapid induction of
photoreceptor cell death that appears to be the result of
apoptosis. Chen et al. [26] found that the retina of Grk−/− mice
raised in darkness had the same morphology as Grk+/+ mice.
However, constant light exposure of Grk−/− mice resulted in
degeneration, causing light-induced apoptosis in the rods
lacking Grk1.
The biochemical effect of the mutations in GRK1 in
patients with Oguchi disease has been studied by Khani et al.
[9], who found the compound heterozygous p.V380D and
p.S536fsX6 variants in a European patient. A comparison of
the functional characteristics of the wild-type and these two
mutant proteins showed that both mutant proteins had
decreased catalytic activity, demonstrating their pathogenic
nature [9]. In addition to the GRK1 missense, null and
frameshift mutations identified by different groups, many
Oguchi disease patients have been shown to carry deletions
of one or more exons of the gene [4-9]. The novel nonsense
mutation (p.S205X) in GRK1 in RP19 described here is
located in the catalytic protein kinase domain (aa196–219),
and is predicted to result in premature termination of the
protein product and as such results in a nonfunctional
rhodopsin kinase.
Our study has resulted in the identification of the first
typical Oguchi family in Pakistan with a novel mutation in
GRK1. This study also demonstrates the power of genetic
studies to correctly diagnose the disease. Previously this
family was classified as having RP, but our diagnostic clinical
tests and genetic data revealed that this family has Oguchi
disease.
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